BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 19240260)

  • 1. Role of huperzine a in the treatment of Alzheimer's disease.
    Desilets AR; Gickas JJ; Dunican KC
    Ann Pharmacother; 2009 Mar; 43(3):514-8. PubMed ID: 19240260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Huperzine a: an acetylcholinesterase inhibitor with high pharmacological potential].
    Pilotaz F; Masson P
    Ann Pharm Fr; 1999 Sep; 57(5):363-73. PubMed ID: 10520506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease.
    Zhang HY; Tang XC
    Trends Pharmacol Sci; 2006 Dec; 27(12):619-25. PubMed ID: 17056129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
    Zhang Z; Wang X; Chen Q; Shu L; Wang J; Shan G
    Zhonghua Yi Xue Za Zhi; 2002 Jul; 82(14):941-4. PubMed ID: 12181083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies.
    Ha GT; Wong RK; Zhang Y
    Chem Biodivers; 2011 Jul; 8(7):1189-204. PubMed ID: 21766442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huperzine A (shuangyiping): a promising drug for Alzheimer's disease.
    Tang XC
    Zhongguo Yao Li Xue Bao; 1996 Nov; 17(6):481-4. PubMed ID: 9863136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on huperzine A as a treatment for Alzheimer's disease.
    Little JT; Walsh S; Aisen PS
    Expert Opin Investig Drugs; 2008 Feb; 17(2):209-15. PubMed ID: 18230054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Huperzine A from Huperzia species--an ethnopharmacolgical review.
    Ma X; Tan C; Zhu D; Gang DR; Xiao P
    J Ethnopharmacol; 2007 Aug; 113(1):15-34. PubMed ID: 17644292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and in vitro and in vivo release studies of Huperzine A loaded microspheres for the treatment of Alzheimer's disease.
    Liu WH; Song JL; Liu K; Chu DF; Li YX
    J Control Release; 2005 Oct; 107(3):417-27. PubMed ID: 16154224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.
    Xu SS; Gao ZX; Weng Z; Du ZM; Xu WA; Yang JS; Zhang ML; Tong ZH; Fang YS; Chai XS
    Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):391-5. PubMed ID: 8701750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia.
    Zhang HY; Zheng CY; Yan H; Wang ZF; Tang LL; Gao X; Tang XC
    Chem Biol Interact; 2008 Sep; 175(1-3):396-402. PubMed ID: 18565502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huperzine A for Alzheimer's disease.
    Li J; Wu HM; Zhou RL; Liu GJ; Dong BR
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005592. PubMed ID: 18425924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Huperzine A--an interesting anticholinesterase compound from the Chinese herbal medicine.
    Patocka J
    Acta Medica (Hradec Kralove); 1998; 41(4):155-7. PubMed ID: 9951045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease.
    Wang R; Tang XC
    Neurosignals; 2005; 14(1-2):71-82. PubMed ID: 15956816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
    Cummings JL; Mackell J; Kaufer D
    Alzheimers Dement; 2008 Jan; 4(1):49-60. PubMed ID: 18631950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase.
    Zhang HY; Yan H; Tang XC
    Cell Mol Neurobiol; 2008 Feb; 28(2):173-83. PubMed ID: 17657601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman.
    Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP
    Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of huperzine A in mild to moderate Alzheimer disease.
    Rafii MS; Walsh S; Little JT; Behan K; Reynolds B; Ward C; Jin S; Thomas R; Aisen PS;
    Neurology; 2011 Apr; 76(16):1389-94. PubMed ID: 21502597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
    Grossberg GT
    Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alzheimer's disease therapy--theory and practice].
    Gabryelewicz T; Barcikowska M; Jarczewska DL
    Wiad Lek; 2005; 58(9-10):528-35. PubMed ID: 16529064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.